Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Kocaturk, Emek; BÜLBÜL BAŞKAN, EMEL; SU KÜÇÜK, ÖZLEM; Ozdemir, MUSTAFA; Ornek, Sinem; Can, Pelin; Hasal, Eda; ENGİN, BURHAN; Atakan, Nilgun; ALPSOY, ERKAN

doi:10.1016/j.abd.2022.03.003

Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Kocaturk E., BÜLBÜL BAŞKAN E., SU KÜÇÜK Ö., Ozdemir M., Ornek S., Can P. K., ...Daha Fazla

ANAIS BRASILEIROS DE DERMATOLOGIA, cilt.97, sa.5, ss.592-600, 2022 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 97 Sayı: 5
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.abd.2022.03.003
Dergi Adı: ANAIS BRASILEIROS DE DERMATOLOGIA
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
Sayfa Sayıları: ss.592-600
Anahtar Kelimeler: Biomarker, Chronic urticaria, Cyclosporine, Omalizumab, BIOMARKERS
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.